The Real-Life Efficacy and Safety of Telmisartan in Patients With Arterial Hypertension

Bayer5,448 enrolled

Overview

The main purpose of this study is to asses the efficacy and safety of telmisartan, with the special attention on the influence of telmisartan on selected metabolic parameters of patients.

Study Type

OBSERVATIONAL

Enrollment

5,448

Conditions

Hypertension

Interventions

Pritor (Telmisartan , BAY68-9291)DRUG

Primary care hypertensive patients starting the therapy with Telmisartan

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age over 18 * Untreated or ineffectively treated arterial hypertension Exclusion Criteria: * Cholestatic disorders and severe hepatic failure * Allergy to telmisartan * Pregnancy and lactation period

Locations (4)

Unnamed facility

Many Locations, Croatia

Unnamed facility

Many Locations, Poland

Unnamed facility

Many Locations, Slovakia

Unnamed facility

Many Locations, Slovenia

Outcomes

Primary Outcomes

Efficacy and safety of the treatment with telmisartan reported by the physician

Time frame: At the both of planned control visits. (Approx. interval between visits 3 months)

Secondary Outcomes

Changes in metabolic parameters in telmisartan treated patients

Time frame: At the both of planned control visits. (Approx. interval between visits 3 months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.